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ABSTRACT
Myocardial infarction afflicts close to three quarters of a
million Americans annually, resulting in reduced heart
function, arrhythmia, and frequently death. Cardiomy-
ocyte death reduces the heart’s pump capacity while the
deposition of a non-conductive scar incurs the risk of
arrhythmia. Direct cardiac reprogramming emerged as a
novel technology to simultaneously reduce scar tissue
and generate new cardiomyocytes to restore cardiac
function. This technology converts endogenous cardiac
fibroblasts directly into induced cardiomyocyte-like
cells using a variety of cocktails including transcription
factors, microRNAs, and small molecules. Although
promising, direct cardiac reprogramming is still in its
fledging phase, and numerous barriers have to be
overcome prior to its clinical application. This review
discusses current findings to optimize reprogramming
efficiency, including reprogramming factor cocktails and
stoichiometry, epigenetic barriers to cell fate repro-
gramming, incomplete conversion and residual fibrob-
last identity, requisite growth factors, and environmental
cues. Finally, we address the current challenges and
future directions for the field.
KEYWORDS cardiac reprogramming, myocardial
infarction, epigenetics, heart regeneration
INTRODUCTION
As the leading cause of death in the United States, heart
disease accounts for one out of every four mortalities
(Heart Disease Fact Sheet CDC, 2016). Contributing to
this, every year 735,000 Americans experience a
myocardial infarction (Heart Attack Facts & Statistics CDC,
2016) which reduces the heart’s pump capacity due to
cardiomyocyte death and increases the risk of arrhythmia
from the deposition of non-conductive scar tissue. There are
currently three primary approaches to cardiac regeneration
as a therapy for myocardial infarction: 1) progenitor cell
transplantation, 2) induced proliferation of resident car-
diomyocytes, and 3) non-myocyte cell fate reprogramming.
The first, progenitor cell therapy, is limited by the low viability
and integration of transplanted cells. Multiple clinical trials
have demonstrated that the engraftment rate of transplanted
cells and the number of cardiomyocytes derived from
transplanted progenitors are insufficient to produce a ther-
apeutic effect (Lin and Pu, 2014). However, some clinical
benefit is observed due to paracrine signaling from the
transplanted progenitors (Lin and Pu, 2014). Identification of
the contributing factors will produce the same effect while
bypassing transplantation altogether (Lin and Pu, 2014).
The second approach, inducing myocyte cell cycle re-entry,
is accompanied by both efficacy and safety concerns.
Studies have yet to demonstrate that the proposed methods
for stimulating cardiomyocyte proliferation can generate a
sufficient quantity of new cardiomyocytes to produce a
clinically relevant effect (Lin and Pu, 2014). Furthermore,
induced proliferation approaches must demonstrate car-
diomyocyte-selective stimulation to preclude oncogenesis
(Lin and Pu, 2014). The third approach, cell fate repro-
gramming of endogenous non-myocytes, is addressed in
this review.
Cell fate reprogramming confers a dual advantage of
reducing scar tissue while simultaneously generating new
cardiomyocytes. Following coronary artery ligation, direct
cardiac reprogramming reduces scar size in murine hearts
by over two-fold (Qian et al., 2012; Song et al., 2012). New
fibroblast-derived reprogrammed cardiomyocytes comprise
35% of cardiomyocytes in the infarct and border zones (Qian
et al., 2012). These newly reprogrammed cardiomyocytes
exhibit integration into the working myocardium, with
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electrical connectivity to endogenous cardiomyocytes and
coordinated contraction (Qian et al., 2012; Song et al.,
2012). Concomitant with measurably reducing scar size and
generating new cardiomyocytes, direct cardiac reprogram-
ming demonstrates substantial therapeutic benefit. Repro-
gramming therapy improves ejection fraction, stroke volume,
and cardiac output in murine hearts following coronary artery
ligation (Qian et al., 2012; Song et al., 2012) and sustains
improvement up to 12 weeks after myocardial infarction
(Song et al.,2012), demonstrating its potential as a thera-
peutic approach. With the in situ regeneration of mature,
functional cardiomyocytes and simultaneous reduction in
scar tissue, direct cardiac reprogramming has strong
potential as a clinical therapy to restore cardiac function
following myocardial infarction. Although significant advan-
ces have been made, studies have uncovered numerous
molecular barriers to the reprogramming process (Fig. 1).
This review explores the molecular barriers to cell fate con-
version in order to facilitate effective and complete direct
cardiac reprogramming.
REPROGRAMMING FACTOR COCKTAILS
Observation that only a fraction of the starting cell population
fully reprograms into functional cardiomyocytes has promp-
ted numerous initiatives to screen candidate reprogramming
factors in order to identify cocktails for optimal reprogram-
ming efficiency. Studies have screened cocktails of tran-
scription factors (Song et al., 2012; Ieda et al., 2010; Protze
et al., 2012; Christoforou et al., 2013; Addis et al., 2013),
microRNAs (Jayawardena et al., 2012 2015), small mole-
cules (Fu et al., 2015; Mohamed et al., 2016), and combi-
nations of the three (Ifkovits et al., 2014; Wang et al., 2014;
Muraoka et al., 2014) (Table 1).
Direct cardiac reprogramming was first described using a
transcription factor cocktail. Ieda et al. screened a pool of
fourteen cardiac lineage transcription factors to define a
cocktail of three reprogramming factors—Gata4, Mef2c, and
Tbx5 (GMT)—that are necessary and sufficient to convert
fibroblasts to induced cardiomyocyte-like cells (iCMs) both
in vitro (Ieda et al., 2010; Wang et al., 2015a) and in vivo
(Qian et al., 2012; Inagawa et al., 2012; Ma et al., 2015).
Subsequently, Song et al. screened six conserved cardiac
lineage transcription factors to identify a cocktail of Gata4,
Hand2, Mef2c, and Tbx5 (GHMT) that generates almost five-
fold more cTnT/αMHC-GFP double positive iCMs than GMT
in vitro (Song et al., 2012). The GHMT cocktail also gener-
ates iCMs in murine hearts in vivo, reducing scar size and
improving cardiac function following myocardial infarction
(Song et al., 2012). While the above mentioned studies
employed sequential subtraction of candidate factors and
αMHC-GFP reporter expression to screen cocktails, Protze
et al. tested all possible triplet combinations of ten repro-
gramming factors and used quantitate PCR for multiple
cardiac markers to identify a three factor reprogramming
cocktail of Mef2c, Tbx5, and Myocd that induces expression
of a broad range of cardiac genes (Protze et al., 2012).
Christoforou et al. furthermore demonstrated that a five or a
seven factor cocktail adding Myocd, SRF, Mesp1, and
SMARCD3 to the three factor GMT cocktail enhances cTnT
mRNA expression by almost five-fold (Christoforou et al.,
2013). Finally, Addis et al. employed a calcium reporter to
functionally screen candidate factors and define a five factor
cocktail of Hand2, Nkx2.5, Gata4, Mef2c, and Tbx5
(HNGMT) for maximally efficient reprogramming of functional
iCMs (Addis et al., 2013).
In addition to transcription factor cocktails, microRNA
combinations successfully generate reprogrammed iCMs.
Jayawardena et al. screened six candidate microRNAs
selected for their regulatory role in cardiomyocyte differenti-
ation and development, transfecting cardiac fibroblasts with
all 41 permutations of singlet, doublet, and triplet microRNA
combinations and screening using quantitative PCR for
cardiac markers (Jayawardena et al., 2012). A cocktail of
miR-1, miR-133, miR-208, and miR-499 is sufficient to
reprogram cardiac fibroblasts both in vitro (Jayawardena
et al., 2012) and in vivo (Jayawardena et al., 2015). The
microRNA cocktail generates functional, mature iCMs in vivo
and reduces scar size and improves cardiac function in
murine hearts following myocardial infarction (Jayawardena
et al., 2015). The mechanism of miR-1 and miR-133
enhancement of reprogramming is discussed below in the
“REPRESSION OF FIBROBLAST IDENTITY” section.
Chemical cocktails for direct cardiac reprogramming have
also been developed, circumventing the genetic manipula-
tion associated risks involved in transcription factor and
microRNA cocktails. Fu et al. noted the emergence of
spontaneously beating cells during iPSC reprogramming
using a cocktail of small molecule compounds and devel-
oped a two-step reprogramming process to induce and sta-
bilize iCM reprogramming (Fu et al., 2015). This two-step
chemical cocktail reprogramming generates beating clusters
of iCMs that express cardiac markers, assemble contractile
sarcomeres, and display cardiomyocyte-like electrophysical
properties without going through a pluripotent stage (Fu
et al., 2015).
In addition to pure cocktails of transcription factors,
microRNA, or small molecules, combinations of factors
produce a synergistic effect for maximal reprogramming
efficiency. Wang et al. directly reprogrammed fibroblasts into
iCMs without going through a pluripotent intermediate state
using a chemical cocktail plus a single transcription factor
Oct4 (Wang et al., 2014). Conversely, Ifkovits et al. used a
single small molecule TGFβ inhibitor to enhance repro-
gramming efficiency of the transcription factor cocktail
HNGMT by five-fold (Ifkovits et al., 2014). Mohamed et al.
found that WNT and TGFβ inhibitors enhance GMT tran-
scription factor cocktail reprogramming by eight-fold (Mo-
hamed et al., 2016). The effects of TGFβ and WNTsignaling
in reprogramming are discussed below in the “REPRES-
SION OF FIBROBLAST IDENTITY” and “INTRACELLULAR
SIGNALING PATHWAYS” sections. Muraoka et al. found
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Table 1. Cocktails for direct cardiac reprogramming of mouse fibroblasts in vitro and in vivo (*)
Transcription Factor Cocktails
Gata4, Mef2c, Tbx5 (GMT)* Ieda et al. (2010)
Gata4, Hand 2, Mef2c, Tbx5 (GHMT)* Song et al. (2012)
Mef2c, Tbx5, Myocd Protze et al. (2012)
Gata4, Mef2c, Tbx5, Myocd, SRF, Mesp1, SMARCD3 Christoforou et al. (2013)
Hand2, Nxk2.5, Gata4, Mef2c, Tbx5 (HNGMT) Addis et al. (2013)
MicroRNA Cocktail
miR-1, miR-133, miR-208, miR-499* Jayawardena et al. (2012)
Chemical Cocktail
CHIR99021, RepSox, Forskolin, VPA, Parnate, TTNPB Fu et al. (2015)
Combined Cocktails
MicroRNA cocktail + JAK inhibitor I Jayawardena et al. (2012)
Chemical cocktail + Oct4 Wang et al. (2014)
HNGMT + TGFβ inhibitor Ifkovits et al. (2014)
GMT + miR-1/miR-133 Muraoka et al. (2014)
GMT + WNT/TGFβ inhibitor Mohamed et al. (2016)
↑
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Figure 1. Exogenous factors including reprogramming factor cocktails and stoichiometry and environmental stimuli alter
intracellular signaling pathways and epigenetic repatterning to suppress fibroblast gene expression and promote
cardiomyocyte gene expression to enhance direct cardiac reprogramming.
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that miR-1 or miR-133 together with the transcription factor
cocktail GMT produced a six-fold increase over GMT alone
(Muraoka et al., 2014). The mechanism of miR-1 and miR-
133 enhancement of reprogramming is also discussed below
in the “REPRESSION OF FIBROBLAST IDENTITY” sec-
tion. Jayawardena et al. used a small molecule compound,
JAK inhibitor I, in combination with the microRNA cocktail
miR-1, miR-133, miR-208, and miR-499 to increase repro-
gramming efficiency by ten-fold (Jayawardena et al., 2012).
REPROGRAMMING FACTOR STOICHIOMETRY
Decades of research in developmental biology have
revealed the fine balance of transcription factor expression
that is required to initiate and maintain cardiac lineage
commitment. However, in cell fate reprogramming, the
forced overexpression of reprogramming factors results in
crude, artificial transcription factor dosage. Most studies
using the standard Gata4, Mef2c, Tbx5 cocktail utilize
retroviral delivery of the three factors packaged as separate
viruses. Starting cells must take up each of the three indi-
vidual viruses in order to be reprogrammed, leading to low
cell fate conversion rates since only a subset of cells receive
all three factors. Individual cells also receive different ratios
of the three factors. Stochastically, only a small fraction of
cells receive the optimal reprogramming factor ratio and
dose for cell fate reprogramming.
To address reprogramming factor stoichiometry, our lab
determined the optimal ratio of the three transcription factors
for efficient reprogramming by creating six polycistronic
constructs with the three factors in every possible splice
order separated by 2A peptide cleavage sites (Wang et al.,
2015a). Splice order dictates protein expression level, with
highest protein expression for the factor in the first position
and lower protein expression for the factors in the second
and third positions (Wang et al., 2015a). Only the Mef2c-
Gata4-Tbx5 (MGT) and Mef2c-Tbx5-Gata4 (MTG) con-
structs, which have Mef2c in the first position, increase
reprogramming efficiency compared to infection with three
separate Gata4, Mef2c, and Tbx5 viruses (Wang et al.,
2015a). The other four constructs decreased αMHC-GFP
iCM reporter expression compared to reprogramming with
separate viruses (Wang et al., 2015a). The highest reporter
expression was achieved using the MGT splice order with
concomitantly higher levels of Mef2c and lower levels of
Gata4 and Tbx5 (Wang et al., 2015a). The optimal poly-
cistronic MGT vector improved both αMHC-GFP reporter
expression and cTnT cardiac marker expression compared
to separate Gata4, Mef2c, Tbx5 virus reprogramming (Wang
et al., 2015a). The polycistronic MGT vector generated
reprogrammed cells that formed iCM clusters, assembled
cTnT and α-Actinin positive sarcomeres, expressed the gap
junction protein Connexin 43, exhibited calcium flux, and
contracted spontaneously (Wang et al., 2015a). Molecular
characterization also shows that the MGT and MTG poly-
cistronic vectors induce higher expression of cardiomyocyte
genes and lower expression of cardiac stress genes Nppa
and Nppb than reprogramming with separate viruses (Wang
et al., 2015a). An optimized protocol for reprogramming
using the polycistronic MGT system was described as an
additional resource (Wang et al., 2015b).
We also demonstrated that optimal reprogramming factor
stoichiometry using the polycistronic MGT vector improves
reprogramming efficiency in vivo in a mouse model of
myocardial infarction (Ma et al., 2015). Using Periostin-Cre;
R26R-lacZ genetic lineage tracing, cells of fibroblast origin
were irreversibly marked with β-galactosidase to identify
iCMs generated from fibroblasts (Ma et al., 2015). In vivo
reprogramming with polycistronic MGT following coronary
artery ligation increases the number of α-Actinin/β-galac-
tosidase double positive iCMs compared to reprogramming
with separate Gata4, Mef2c, Tbx5 viruses (Ma et al., 2015).
Additionally, in vivo reprogramming with the polycistronic
MGT vector produces greater functional improvement in
fractional shortening and ejection fraction and reduces scar
size following myocardial infarction than reprogramming with
separate viruses (Ma et al., 2015). Optimal stoichiometry of
the three transcription factors using a polycistronic vector
increases the efficiency of in vivo reprogramming and further
improves cardiac function following myocardial infarction
(Ma et al., 2015).
In addition to defining the optimal reprogramming factor
stoichiometry, we created an inducible system where poly-
cistronicMGTexpression is both temporally and quantitatively
regulated through the administration of doxycycline (Vaseghi
et al., 2016). Using the TetOn inducible gene expression
system, reprogramming factor expression is tightly regulated
by the presence of doxycycline in the cell culture media
(Vaseghi et al., 2016). Additionally, by titrating the doxycycline
concentration, reprogramming factor expression level and
dosage can be controlled (Vaseghi et al., 2016).
Two other in vivo studies also created polycistronic
reprogramming vectors. Inagawa et al. placed the repro-
gramming factors in the order Tbx5-Mef2c-Gata4 (Inagawa
et al., 2012), while Mathison et al. used the order Gata4-
Mef2c-Tbx5 (Mathison et al., 2014). Both studies demon-
strate a modest increase in reprogramming efficiency using
their single polycistronic vector compared to three separate
viruses, but the improvement is only incremental due to the
non-optimal dosage of the reprogramming factors.
Inagawa et al. found no difference in the proportion of
α-Actinin positive reprogrammed cells to infected cells
between their polycistronic TMG vector and separate viruses
but did see the proportion of α-Actinin positive cells that had
assembled sarcomeres double from 15% to 30% of infected
cells (Inagawa et al., 2012). Mathison et al. demonstrated
increased numbers of reprogrammed cells in vitro and
improved cardiac function in vivo using their GMT poly-
cistronic vector (Mathison et al., 2014). The incremental
improvement demonstrated by these polycistronic systems
is possibly due to the increased delivery of all three repro-
gramming factors to the starting cell population, although the
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optimal dosage of the reprogramming factors was not
considered.
EPIGENETIC BARRIERS TO DIRECT CARDIAC
REPROGRAMMING
In addition to reprogramming factor dosage and timing, the
epigenetic regulation of gene expression programs is critical
to cell lineage commitment. Highlighting the role of epige-
netic modulation in cell fate determination and conversion,
Takeuchi and Bruneau directed ectopic differentiation of
embryonic mouse mesoderm into beating cardiomyocytes
using transient transfection of the cardiac transcription factor
Gata4 and the cardiac specific chromatin remodeling com-
plex subunit, Baf60c (Takeuchi and Bruneau, 2009). Baf60c
potentiates the binding of Gata4 to DNA at cardiac loci to
turn on ectopic cardiac gene expression (Takeuchi and
Bruneau, 2009). Transfection of the transcription factor Tbx5
in addition to Gata4 and Baf60c promotes the complete dif-
ferentiation of transfected cells into beating cardiomyocytes
(Takeuchi and Bruneau, 2009). The transfected cells begin
beating even before the endogenous heart field starts to
form (Takeuchi and Bruneau, 2009). Baf60c is one of the
minimal requirements for this ectopic cardiac differentiation
of the embryonic mesoderm, demonstrating that chromatin
remodeling plays a crucial role in transdifferentiation and
cardiac fate acquisition. Cellular reprogramming necessarily
involves changes to the epigenetic landscape. Epigenetic
marks must be erased and re-written to alter chromatin
structure and gene expression patterns during reprogram-
ming as the fibroblast signature is repressed and a car-
diomyocyte gene expression program is activated. Recent
studies have demonstrated that epigenetic manipulation can
potentiate the reprogramming process.
Epigenetic regulation of gene transcription is mediated
through histone post-translational modification, including
histone acetylation. Studies in cardiac development suggest
that histone deacetylase (HDAC) inhibition directs cells
toward a cardiac lineage fate (Karamboulas et al., 2006;
Chen et al., 2011). Overexpression of HDAC4, a class IIa
HDAC, inhibits cardiac muscle development, while class IIa
HDAC inhibition restores cardiomyogenesis (Karamboulas
et al., 2006). Commitment to the cardiac lineage is accom-
panied by the upregulation of Gata4, Mef2c, and other key
cardiac transcription factors (Karamboulas et al., 2006);
however, class IIa HDACs repress cardiac transcription
factors, including Gata4 and Mef2 family transcription factors
(McKinsey and Olson 2004; Miska et al., 1999). Conse-
quently, HDAC inhibition promotes cardiomyogenesis and
upregulates the expression of cardiac transcription factors
Gata4, Mef2c, and Nkx2.5, among others (Chen et al., 2011).
Simultaneous induction of reprogramming factor expression
and HDAC inhibition using valproic acid, a non-specific
HDAC inhibitor, enhances direct cardiac reprogramming,
increasing the proportion of cTnT or α-Actinin positive
reprogrammed cells by two-fold (Christoforou et al., 2013).
These findings suggest that HDAC inhibition may enhance
direct cardiac reprogramming by epigenetically priming cells
for cardiac fate acquisition.
Widespread epigenetic repatterning occurs during direct
cardiac reprogramming. Zhao et al. performed chromatin
immunoprecipitation sequencing of H3K4me2, which marks
the promoters and enhancers of transcriptionally active
genes, and demonstrated that one week after GHMTcocktail
reprogramming 47% of the H3K4me2 peaks had shifted to
align with those of primary cardiomyocytes (Zhao et al.,
2015). Our lab demonstrated that trimethylation of lysine 27
on histone 3 (H3K27me3), a repressive epigenetic mark, is
depleted and trimethylation of lysine 4 on histone 3
(H3K4me3), an activating histone modification, is enriched at
cardiac promoters early in GMT cocktail reprogramming and
is accompanied by a rapid increase in cardiac gene mRNA
expression (Liu et al., 2016a). This early activation of the
cardiomyocyte gene expression program is later followed by
the increase of H3K27me3 and decrease of H3K4me3 at
fibroblast loci and a concomitant decrease in fibroblast gene
mRNA expression (Liu et al. 2016a). These findings suggest
that reprogramming activates cardiac gene expression first,
followed by later repression of fibroblast gene expression.
Similarly, Dal-Pra et al. demonstrated that H3K27 demethy-
lation is required for the induction of cardiac gene expression
during microRNA cocktail reprogramming (Dal-Pra et al.,
2017). Reprogramming with a miR-1, miR-133, miR-208,
miR-499 microRNA cocktail alters H3K27 methyltransferase
and demethylase expression, inducing a 40% and 50%
increase in expression of the two H3K27 demethylases
Kdm6B and Kdm6A respectively and a 50% decrease in
expression of the H3K27 methyltransferase Ezh2 at both the
mRNA and protein level (Dal-Pra et al., 2017). Consequently,
reprogramming reduces global H3K27me3 by 40% (Dal-Pra
et al., 2017). Specifically, promoters of cardiac transcription
factors Tbx5, Mef2c, and Gata4 exhibit a 50% reduction in
H3K27me3 (Dal-Pra et al., 2017). Pharmacologic inhibition
of H3K27 methyltransferase activity reduces H3K27me3 by
30% and increases gene and protein expression of cardiac
markers between two- to eight-fold irrespective of microRNA
cocktail reprogramming (Dal-Pra et al., 2017). Conversely,
knockdown of H3K27 demethylase activity inhibits the
induction of cardiac marker expression during microRNA
cocktail reprogramming (Dal-Pra et al., 2017). These find-
ings demonstrate that H3K27 demethylation and de-repres-
sion of cardiac loci is essential for direct cardiac
reprogramming.
Given that extensive repatterning of histone modifications
occurs during the reprogramming process, modulation of the
deposition and removal of histone modifications may pro-
mote greater reprogramming efficiency. Hirai et al. used a
small molecule inhibitor of Ezh2, the catalytic component of
the PRC2 complex catalyzing H3K27me2/3, to demonstrate
that Ezh2 inhibition early in reprogramming increases
reprogramming efficiency (Hirai and Kikyo, 2014). The
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authors also report that late inhibition of the methyltrans-
ferase G9a, which catalyzes H3K9me1/2, increases repro-
gramming efficiency (Hirai and Kikyo, 2014). Conversely,
Ifkovits et al. found that pre-treatment of fibroblasts with a
G9a histone methyltransferase inhibitor reduced repro-
gramming efficiency (Ifkovits et al., 2014), demonstrating
that the timing of histone methyltransferase inhibition is
crucial for its effect on reprogramming. Hirai et al. observed
that only specific time windows of drug administration were
sufficient to promote an increase in reprogrammed cells and
that inhibition at other times resulted in no effect or a
decrease in reprogramming efficiency (Hirai and Kikyo,
2014). The two histone methyltransferases inhibited by Hirai
et al., Ezh2 and G9a, require inhibition at different times to
promote increased reprogramming (Hirai and Kikyo, 2014).
While early inhibition of Ezh2 resulted in maximal generation
of iCM clusters, late inhibition of G9a promoted iCM gener-
ation (Hirai and Kikyo, 2014), indicating that the timing of
histone methyltransferase inhibition is critical to enhancing
reprogramming.
To identify key epigenetic barriers to the reprogramming
process, we conducted a comprehensive loss-of-function
screen of epigenetic modifying factors and identified Bmi1 as
a critical epigenetic inhibitor of reprogramming (Zhou et al.,
2016). Bmi1 is a polycomb group protein that directly binds
to cardiac loci and suppresses expression of cardiac genes
(Zhou et al., 2016). Depleting Bmi1 increases H3K4me3 and
reduces H2AK119ub at cardiac loci and subsequently de-
represses cardiac gene expression, priming fibroblasts for
reprogramming (Zhou et al., 2016). Bmi1 knockdown plays a
role to enhance cardiac fate acquisition early in the repro-
gramming process, as late Bmi1 depletion does not affect
reprogramming (Zhou et al., 2016). Bmi1 also directly binds
to the regulatory region and modulates the expression of
Gata4 (Zhou et al., 2016). The inhibition of Bmi1 de-re-
presses endogenous Gata4 expression and can therefore
replace exogenous Gata4 in the Gata4, Mef2c, Tbx5 repro-
gramming cocktail (Zhou et al., 2016), permitting two factor-
mediated iCM reprogramming to be possible.
In a similar approach, Liu et al. conducted a gain-of-
function screen of cardiac development epigenetic modifiers
and transcription factors and identified the H3K4 methyl-
transferase Mll1 as a barrier to direct cardiac reprogramming
(Liu et al., 2016b). Pharmacologic inhibition of Mll1 improves
both iCM generation with a 1.5-fold increase in αMHC-GFP
reporter expression and iCM maturation with increased
sarcomere assembly and spontaneous beating (Liu et al.,
2016b). Inhibition of Mll1 directs cardiomyocyte cell fate
specification by suppressing adipocyte lineage transdiffer-
entiation (Liu et al., 2016b). Mll1 inhibition prevents MGT-
mediated upregulation of adipocyte genes and adipocyte
formation as indicated by Oil Red O staining (Liu et al.,
2016b). The adipocyte associated gene Ebf1 is a key target
of Mll1, and the reduction in Ebf1 expression caused by Mll1
inhibition mediates the observed increase in reprogramming
efficiency (Liu et al., 2016b).
REPRESSION OF FIBROBLAST IDENTITY
Direct cardiac reprogramming is accomplished through the
activation of cardiac gene expression but must also be
accompanied by complete silencing of the original fibroblast
signature. Characterization of epigenetic repatterning during
reprogramming by Liu et al. demonstrates a gradual
repression of fibroblast loci (Liu et al., 2016a). Chromatin
immunoprecipitation followed by real time PCR reveals late
deposition of the repressive H3K27me3 histone modification
at fibroblast marker gene promoters and fibroblast-enriched
transcription factor promoters with a concomitant decrease
in mRNA expression (Liu et al., 2016a).
Maintenance of residual fibroblast gene expression pre-
sents a roadblock to the successful reprogramming of func-
tionally mature cardiomyocytes. MicroRNAs miR-1 and miR-
133 enhance direct cardiac reprogramming by suppressing
fibrotic gene expression (Muraoka et al., 2014; Zhao et al.,
2015). Overexpression of miR-1 and miR-133 together with
reprogramming cocktails generates more spontaneously
beating iCMs faster than reprogramming cocktails alone
(Muraoka et al., 2014; Zhao et al., 2015). Reprogramming
with miR-133 also generates more iCMs exhibiting sponta-
neous calcium oscillations than transcription factor cocktails
alone (Muraoka et al., 2014). A combination of both miR-1
and miR-133 with transcription factor reprogramming cock-
tails was the most efficient treatment for generating sponta-
neously beating iCMs (Zhao et al., 2015). MiR-133
overexpression represses fibroblast gene expression
through the suppression of Snai1 (Muraoka et al., 2014).
Snai1 knockdown suppresses fibroblast gene expression
and promotes cardiac gene expression in reprogramming,
while Snai1 overexpression maintains fibroblast gene
expression and inhibits the development of spontaneous
beating in iCMs (Muraoka et al., 2014). These studies indi-
cate that microRNA repression of fibroblast gene expression
improves reprogramming speed and iCM functional maturity.
In another approach to erasing fibroblast identity, studies
have used inhibition of pro-fibrotic signaling pathways to
enhance reprogramming efficiency (Ifkovits et al., 2014;
Zhao et al., 2015). Silencing pro-fibrotic transforming growth
factor beta (TGFβ) signaling and Rho-associated kinase
(ROCK) signaling increases iCM conversion numbers and
speed (Ifkovits et al., 2014; Zhao et al., 2015). Conversely,
overexpression of these pathways inhibits the reprogram-
ming process (Ifkovits et al., 2014; Zhao et al., 2015).
Maintenance of pro-fibrotic signaling leads to incompletely
converted cells; however, reprogramming factor expression
is sufficient to activate pro-fibrotic signaling, which must be
subsequently suppressed for successful conversion (Zhao
et al., 2015). Early administration or pre-treatment with a
TGFβ silences pro-fibrotic signaling to enhance reprogram-
ming efficiency (Mohamed et al. 2016; Ifkovits et al., 2014).
In conjunction with miR-1 and miR-133 overexpression,
ROCK or TGFβ further represses fibroblast gene expression
and increases reprogramming efficiency and speed,
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suggesting a synergistic barrier to reprogramming between
pro-fibrotic signaling and microRNA fibroblast gene regula-
tion (Zhao et al., 2015). Similarly, dual inhibition of TGFβWnt
signaling improves the quantity, maturation, and speed of
reprogramming (Mohamed et al., 2016). Early TGFβ inhibi-
tion followed shortly by Wnt inhibition generates an eight-fold
increase in iCMs (Mohamed et al., 2016). These iCMs
exhibit accelerated reprogramming with beating cells
observed as early as one week after reprogramming (Mo-
hamed et al., 2016). TGFβ and Wnt inhibition during repro-
gramming produces iCMs that are transcriptionally more
similar to adult cardiomyocytes than iCMs generated in the
absence of inhibitors (Mohamed et al., 2016). Inhibition of
TGFβ and Wnt signaling affects chromatin accessibility
(Mohamed et al., 2016). Together, the dual inhibition of
TGFβ and Wnt signaling increases expression of mature
cardiomyocyte markers including ion channels, calcium
handling genes, and components of fatty acid metabolism
(Mohamed et al., 2016). These studies demonstrate that
residual fibroblast signature is a barrier to complete cell fate
conversion and that repressing fibroblast gene expression
enhances reprogramming in vitro.
Mohamed et al. demonstrate that repression of residual
fibroblast signature using TGFβ and Wnt inhibition also
enhances reprogramming and cardiac function in vivo (Mo-
hamed et al. 2016). In conjunction with TGFβ and Wnt inhi-
bition, GMT transcription factor cocktail reprogramming
increases ejection fraction, stroke volume, and cardiac output
as early as one week post coronary artery ligation (Mohamed
et al., 2016). Histologic sections reveal that TGFβ and Wnt
inhibition reduces scar size and produces thicker bands of
fibroblast-derived reprogrammed iCMs re-muscularizing the
infarct region (Mohamed et al., 2016). Lineage tracing indi-
cates that TGFβ and Wnt inhibition during reprogramming
produces a five-fold increase in iCM generation compared to
reprogramming without inhibitors (Mohamed et al., 2016).
TGFβ and Wnt inhibition also generates iCMs that are func-
tionally more mature, with calcium and contraction kinetics
more similar to adult cardiomyocytes (Mohamed et al., 2016).
INTRACELLULAR SIGNALING PATHWAYS
Recent studies have examined the effect of intracellular sig-
naling pathways on direct cardiac reprogramming. Zhou et al.
modulated intracellular signaling pathways by screening a
library of 192 protein kinases to assess the effect on GHMT
transcription factor reprogramming (Zhou et al., 2015). Akt1
activation increases reprogramming efficiency and produces
iCMs with a more mature cardiomyocyte phenotype,
exhibiting an increase in calcium flux, spontaneous beating,
polynucleation, cellular hypertrophy, mitochondrial function,
cardiac marker expression, and sarcomere assembly (Zhou
et al., 2015). Akt1 does not enhance the expression of the
GHMT reprogramming factors (Zhou et al., 2015). Rather,
Akt1 functions through its downstream targets, activating
mTOR and inhibiting Foxo3a which have roles in the
regulation of mitochondrial metabolism, myocyte develop-
ment, and gene expression (Zhou et al., 2015).
Abad et al. screened seven small molecule compounds
with a demonstrated role in iPSC reprogramming and found
that the Notch inhibitor DAPT enhances GHMT transcription
factor cocktail reprogramming (Abad et al., 2017). Notch
pathway signaling plays an important role in cardiac devel-
opment by regulating cardiomyocyte differentiation and pro-
liferation (Abad et al.,2017). Non-canonical Notch signaling
blocks the binding of transcription factor Mef2c to promoter
regions (Abad et al., 2017). In the context of iCM repro-
gramming, Notch inhibition acts in coordination with Akt1 to
increase the acquisition of a mature cardiomyocyte pheno-
type, demonstrated by increased calcium flux, sarcomere
assembly, and spontaneous beating (Abad et al., 2017).
GHMT reprogramming with Akt1 activation and Notch inhi-
bition generated up to 70% conversion efficiency with 45% of
the reprogrammed iCMs exhibiting spontaneous beating
(Abad et al., 2017). Notch inhibition modulates transcriptional
programs involved in cardiomyocyte differentiation and
development by increasing the binding of transcription factor
Mef2c to cardiac loci promoters (Abad et al., 2017).
Mohamed et al. screened a library of 5,500 small mole-
cule compounds in an unbiased, high throughput approach
to determine cell signaling pathways that modulate repro-
gramming and identified the WNT and TGFβ signaling
pathways as barriers to reprogramming (Mohamed et al.,
2016). Inhibiting both pathways improves GMT transcription
factor cocktail reprogramming in vitro and in vivo (Mohamed
et al., 2016). TGFβ/Wnt inhibition enhances reprogramming
efficiency and speed in vitro (Mohamed et al., 2016). GMT
reprogramming with both inhibitors produces 30% αMHC-
GFP reporter expression, while only one inhibitor produces
15% and no inhibitors produces only 4% (Mohamed et al.,
2016). GMT reprogramming with both inhibitors generates
beating iCMs within one week, while only one inhibitor
requires three weeks and no inhibitors requires six to eight
weeks (Mohamed et al., 2016). TGFβ/Wnt inhibition also
enhances reprogramming and cardiac function in vivo (Mo-
hamed et al., 2016) (See “REPRESSION OF FIBROBLAST
IDENTITY”). RNA sequencing reveals that iCMs repro-
grammed in the presence of the TGFβ inhibitor downregu-
late fibrotic and extracellular matrix associated genes, while
iCMs reprogrammed in the presence of the WNT inhibitor
downregulate genes affecting chromatin modulation, nucle-
osome organization, and DNA packaging.
GROWTH FACTORS
Multiple studies have noted greater conversion efficiency or
more complete functional maturation of iCMs reprogrammed
in vivo over in vitro (Qian et al., 2012; Song et al., 2012;
Inagawa et al., 2012; Ma et al., 2015). In vivo reprogrammed
iCMs are more similar to endogenous cardiomyocytes than
in vitro reprogrammed iCMs. This suggests that unidentified
extrinsic factors in the in vivo microenvironment such as
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topographic cues, mechanical forces, growth factors,
cytokines, or paracrine signaling play an important role in
promoting iCM maturation.
Lack of requisite growth factors constitutes a barrier to
reprogramming. Yamakawa et al. noted that under serum-
based culture conditions, in vitro reprogramming generated
incompletely converted, immature iCMs (Yamakawa et al.,
2015). Although many reporter positive cells were observed
at early time points, few remained marker positive after four
weeks of culture (Yamakawa et al., 2015). The authors
screened eight cardiogenic compounds to create a serum-
free cell culture media containing fibroblast growth factor
(FGF) 2, FGF10, and vascular endothelial growth factor
(VEGF) that greatly enhances the in vitro generation of
functionally mature iCMs that contract spontaneously and
exhibit calcium oscillations (Yamakawa et al., 2015). The
optimized media (FFV) increases the maturity of repro-
grammed cells by activating cardiac transcriptional regula-
tors, the p38 MAPK pathway, and the PI3K/AKT pathway
(Yamakawa et al., 2015). Additionally, reprogramming with
Mef2c and Tbx5 in FFV media upregulates endogenous
Gata4 expression and removes the requirement for exoge-
nous Gata4 expression as a reprogramming factor (Ya-
makawa et al., 2015), similarly to our findings (Zhou et al.,
2016). The growth factors in FFV media are critical for late
stage maturation but do not affect early reprogramming
events (Yamakawa et al., 2015). Christoforou et al. also
observed that iCMs cultured in high serum media fail to
assemble α-Actinin or cTnT positive sarcomeres (Christo-
forou et al., 2013). Use of low serum growth media increases
the assembly of α-Actinin/cTnT double positive sarcomeres
(Christoforou et al., 2013). However, reprogrammed cells
lose striated sarcomere staining over time. By day 30 most
double positive cells do not exhibit organized sarcomeres
(Christoforou et al., 2013). These studies indicate that the
growth factors in serum-free media help promote iCM mat-
uration and sarcomere assembly.
ENVIRONMENTAL CUES
In addition to growth factors, environmental cues are
important in developing the functional maturity of iCMs.
Cultured cardiomyocytes respond differently to the stiffness
of the in vitro substrate (Chopra et al., 2012). Polyacrylamide
gels with a stiffness between 10–30 kPa favor cardiomy-
ocytes with a spread and elongated morphology that form
well organized, polarized sarcomeres. However, stiff sub-
strates produce cells with F-actin stress fibers that lack
organized sarcomeres, while soft substrates produce cells
with rounded morphology and disorganized sarcomeres.
These findings suggest that the cardiomyocyte cytoskeleton
remodels based on substrate stiffness (Chopra et al., 2012).
However, GMT transcription factor cocktail reprogramming
of adult tail tip fibroblasts on substrates of 1, 21, and 62 kPa
does not have an effect on reprogramming efficiency even
though variation in substrate stiffness successfully induces a
range of morphologies (Sia et al., 2016). Culturing repro-
gramming cells under conditions of periodic uniaxial stretch
also fails to increase reprogramming efficiency, although
cells orient in response (Sia et al., 2016).
While direct cardiac reprogramming is unaffected by
in vitro substrate stiffness or mechanical stretch, repro-
gramming does respond to other topographical cues. Morez
et al. demonstrated that the forward programming of cardiac
progenitor cells using the cardiac lineage transcription factor
cocktail Myocardin, Tbx5, and Mef2c is enhanced by topo-
graphical cues which modulate histone acetylation (Morez
et al., 2015). Sca1+ adult progenitor cells were repro-
grammed on flat or microgrooved collagen I coated poly-
dimethylsiloxane substrates. Reprogramming efficiency and
sarcomere assembly are enhanced on microgrooved sub-
strates compared to flat substrates (Morez et al., 2015).
Culture on microgrooved substrates increases histone 3
acetylation in differentiating cells (Morez et al., 2015).
Treatment with the histone deacetylase inhibitor VPA pro-
duces a similar increase in reprogramming efficiency and
increase in histone 3 acetylation in cells reprogrammed on a
flat substrate (Morez et al., 2015). VPA treatment does not
produce an additive effect on the reprogramming efficiency
of cells cultured on microgrooved substrates, indicating that
culture on microgrooved substrates increases reprogram-
ming through histone acetylation (Morez et al., 2015). Cul-
turing on microgrooved substrates also significantly
enhances iCM sarcomere assembly compared to flat sub-
strates (Morez et al., 2015). Unlike reprogramming effi-
ciency, sarcomere organization is independent of histone 3
acetylation (Morez et al., 2015). These results indicate that
topographical cues improve cardiomyocyte reprogramming
efficiency and maturation (Morez et al. 2015). Furthermore,
Sia et al. demonstrated that GMT reprogrammed adult tail tip
fibroblasts cultured on a microgrooved substrate show
increased reprogramming and beating through a histone
acetylation and transcriptional activation mechanism (Sia
et al., 2016). Cells cultured in microgrooves align along the
grooves and exhibit an elongated morphology (Sia et al.,
2016). Reprogramming in microgrooves generates two-fold
more cTnT positive, sarcomere positive, and beating iCMs
than reprogramming on flat surfaces (Sia et al., 2016).
Microgroove cultured iCMs have 1.5-fold higher nuclear
localization of the mechanosensitive transcription factor Mkl1
than iCMs cultured on flat surfaces (Sia et al., 2016). Bleb-
bistatin treatment prevents Mkl1 nuclear localization and
reduces the reprogramming yield of iCMs on microgrooved
surfaces to that of flat surfaces (Sia et al., 2016). Jasplaki-
nolide and Cytochalasin D promote Mkl1 nuclear localization
and increase the yield of iCMs cultured on flat surfaces to
that of grooved surfaces (Sia et al., 2016). However, over-
expressing Mkl1 during reprogramming on flat surfaces only
partially accounts for the increase in reprogramming seen on
grooved surfaces (Sia et al., 2016). Consistent with the
findings of Morez et al., Sia et al. showed that culturing on
microgrooves increases histone 3 acetylation (Sia et al.,
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2016). Simultaneous VPA HDAC inhibition and Mkl1 over-
expression completely account for the increase in repro-
gramming on grooved surfaces (Sia et al., 2016).
The identity and composition of the extracellular matrix
also impacts cardiomyocyte phenotype and reprogramming.
Substrate adhesive ligands alter cardiomyocyte sarcomere
organization and maturation through integrin signaling.
Sarcomeres are well organized and polarized when car-
diomyocytes are cultured on fibronectin coated polyacry-
lamide substrates but not on collagen I coated
polyacrylamide (Chopra et al., 2012). Culturing cardiomy-
ocytes on hyaluronic acid instead of polyacrylamide gels
partially removes cardiomyocyte dependence on substrate
stiffness and allows cells to organize mature sarcomeres
on softer substrates (Chopra et al., 2012). These findings
suggest that the cardiomyocyte cytoskeleton remodels
based on adhesive ligand signaling (Chopra et al., 2012).
Consequently, extracellular matrix composition also influ-
ences cardiac reprogramming (Kong et al., 2013). Using an
indirect reprogramming method that employs de-differenti-
ation followed by directed cardiac differentiation, Kong et al.
compared reprograming efficiency on hydrogels incorpo-
rating Matrigel, collagen I, or fibrin extracellular matrix
proteins (Kong et al., 2013). Reprogramming on fibrin gels
yields the greatest number of contractile cardiomyocyte
colonies, and supplementation with ascorbic acid, which
promotes cellular collagen synthesis, increases contractile
colony size (Kong et al., 2013). Contractile colonies stain
positive for collagen while non-contractile colonies are
negative (Kong et al., 2013). Furthermore, the addition of
collagen I to fibrin hydrogels promotes cardiac differentia-
tion and increases the generation of contractile colonies
(Kong et al., 2013). These findings demonstrate that the
composition of extracellular matrix proteins for in vitro cell
culture substrates directly alters reprogramming efficiency
and maturity.
To more accurately mimic environmental stimuli in vivo, Li
et al. cultured reprogramming iCMs in a 3D fibrin hydrogel
and demonstrated that 3D culture enhances direct cardiac
reprogramming (Li et al., 2016). Compared with 2D culture,
3D hydrogel culture increases cardiac gene expression and
cTnT and α-Actinin immunostaining in both microRNA
reprogramming cocktail and control microRNA conditions (Li
et al., 2016). While microRNA cocktail reprogramming on
traditional 2D tissue culture plates produces a five-fold
increase in αMHC-CFP reporter expression, reprogramming
in 3D fibrin hydrogels generates a twenty-fold increase in
reporter expression (Li et al., 2016). Fibrin hydrogel 3D
culture also increases matrix metalloproteinase (MMP)
expression (Li et al., 2016). Broad spectrum pharmacologi-
cal inhibition of MMP activity abolishes the increase in
reprogramming from fibrin hydrogel 3D culture, indicating
that 3D culture enhances reprogramming through a MMP-
mediated mechanism (Li et al., 2016). The role of MMPs in
enhancing direct cardiac reprogramming in 3D culture sug-
gests that the upregulation of MMPs in infarcted hearts could
be a contributing factor to the greater reprogramming effi-
ciency in vivo compared to in vitro (Li et al., 2016).
Manipulation of in vivo conditions also has the potential to
improve reprogramming. Promoting angiogenesis through
preconditioning with VEGF increases in vivo reprogramming
efficiency and improves therapeutic restoration of cardiac
function (Mathison et al., 2012). Pro-angiogenic VEGF
treatment increases the vascularization of the infarct zone in
rat hearts following myocardial infarction (Mathison et al.,
2012). VEGF preconditioning also increases the number of
Myh7 positive cardiomyocytes in the infarct zone of GMT
treated hearts and increases ejection fraction by four-fold
(Mathison et al., 2012). Promoting fibroblast activation and
migration through thymosin b4 treatment also enhances
in vivo reprogramming efficiency (Qian et al., 2012). Thy-
mosin b4 injection increases fibroblast proliferation in mouse
hearts following myocardial infarction (Qian et al., 2012).
Thymosin b4 treatment in conjunction with GMT repro-
gramming increases the generation of iCMs, improves car-
diac function, and reduces scar size (Qian et al., 2012).
FUTURE DIRECTION
Additional research is required to translate direct cardiac
reprogramming into a clinical therapy. Necessary steps
include continued basic research, research in large animal
models, improvement in human reprogramming, and bio-
engineering of delivery mechanisms.
A better understanding is needed of the mechanism of late
stage reprogramming events and iCM maturation. Research
in this area is currently hindered by inefficiency in the repro-
gramming process. Asynchronous, heterogeneous cell pop-
ulations produce low rates of fully reprogrammed cellsmaking
it difficult to acquire sufficient cell numbers to study late stage
reprogramming events. Early stage studies are aided by the
comparative synchrony of cells early in the reprogramming
process that provides a large sample population.
Research in large animal models is also required to move
direct cardiac reprogramming toward clinical application. The
efficiency of housing, breeding, and handling rodents has
made them the most widely used animal models in biomed-
ical research. Additionally, a wealth of tools has been
developed specifically for murine research, including imaging
techniques, in vivo monitoring systems, and genetic manip-
ulation, making the mouse a particularly productive model.
However, the mouse exhibits significant cardiovascular dif-
ferences compared to humans. In addition to obvious differ-
ences such as small size and short lifespan, mice differ from
humans in a range of anatomical, physiological, energetic,
electrophysical, and mechanical properties that include heart
rate, coronary artery structure, and contraction/relaxation
kinetics. Large animal models such as the dog, sheep, or pig
have greater physiologic resemblance to humans with similar
body size, heart size, and heart rate. In fact, physiological
similarities between pigs and humans are close enough to
make the pig an ideal xenotransplant donor. Recent progress
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in genetic manipulation of pigs will contribute to the use of the
pig as a cardiovascular disease model.
Although significant progress has been achieved in
uncovering the molecular barriers to direct reprogramming in
mice, research in reprogramming human cells lags far
behind. Reprogramming human fibroblasts requires the
addition of extra factors but yields far lower conversion effi-
ciency. Spontaneously beating cells are rare, indicating that
more work is required to translate findings from the mouse to
human and uncover undiscovered molecular barriers in
human reprogramming.
Finally, a safe and efficient delivery system is required for
the translation of direct cardiac reprogramming to clinical
use. Current in vivo research uses direct injection of retro-
viral vectors into the infarct zone. While conceivably, direct
cardiac injection could be achieved in some myocardial
infarct patients during coronary bypass surgery, a non-in-
vasive delivery method is preferable. Additionally, retroviral
vectors integrate into the host cell genome, incurring the risk
of gene disruption and cellular transformation. The ideal
delivery vector would be non-integrating with high transfec-
tion efficiency, specificity for the target cell type, and ade-
quate capacity to accommodate multiple reprogramming
factors. Adenoviruses are promising viral vectors for the
delivery of reprogramming factors. The most commonly
employed vector in clinical trials, adenoviruses are non-in-
tegrating, with large capacity and high transduction effi-
ciency. Additionally, recent research using small molecules
to achieve reprogramming and developments in nanoparticle
delivery systems offer potential alternatives to viral vector
reprogramming factor delivery.
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